Werner Wenning

Werner Wenning is not mentioned in the provided news articles. The articles focus on Bayer's pharmaceutical division and its strategy for navigating expiring patents on blockbuster drugs. Specifically, they highlight the division's unexpectedly strong performance and the Vorstand's confidence in its current portfolio. The articles mention Stefan Oelrich and his role within the company, but make no reference to Werner Wenning. Therefore, based on the provided information, there is no indication why Werner Wenning would be newsworthy or relevant to the topics discussed in these articles. The articles primarily discuss Bayer's pharmaceutical growth, expectations, and associated risks.